Arcellx’s cell therapy is on hold after patient death in multiple myeloma trial

Arcellx said its autologous cell therapy was put on hold last Friday after the death of a recent patient in a trial testing the biotech’s CAR-modified T cell therapy in relapsed or refractory multiple myeloma.

Rami Elghandour

“The company believes limitations on bridging therapy…